While the intranasal studies reported here were conducted in a preventive mode, similar studies using soluble recombinant mouse ACE2 and the same SARS-COV-2 derivative demonstrated that a therapeutic effect could be demonstrated when treatment was initiated up to 48 hours following infection [20]. Here, ACE2 is linked to infection.